The chirp stimulus was designed seeking to compensate the delay of the sound wave through the cochlea, enabling simultaneous stimulation of nerve fibers along the auditory pathway, providing better neural synchrony and consequently higher amplitude responses. This study aims to analyze and compare the results of brainstem auditory evoked potential in newborns born at term, using the click and iChirp stimuli at different intensities, analyzing latency and amplitude of the V wave, tested ear and genre. The study analyzed 30 newborns at terms, and the protocol for BAEP registry with click and iChirp stimulus was: rarified polarity, 2048 scans, presentation rate of 27.7 stimuli/s, bandpass filter from 100 to 3,000 Hz, 100k gain, 12 ms window for the click and 24 ms for iChirp. Intensities researched with the two stimuli were 60, 40 and 20 dB nHL. When results with the two stimuli used in the study were compared regarding the values for the latency of the V wave, increased values with iChirp were observed in the three levels of performance. In regards to the magnitude of this component, the three researched intensities also revealed that the iChirp stimulus was able to generate statistically significant larger amplitudes when compared to the click stimulus. Additionally, subtle differences were observed between the ears and between the genres for the latency values and V wave amplitude with the different stimuli used, although with little clinical relevance. In conclusion, the use of iChirp stimulus may be interesting in the field of audiological diagnosis in children, since it evokes responses with larger amplitudes in the three intensity levels studied, facilitating the identification of the V wave. It is worth noting that when the iChirp was used, the latency of the V wave was higher when compared to research with the click. The variables ear tested and gender exhibited slight differences that were not considered clinically relavant. / O estímulo chirp foi projetado buscando compensar o atraso da onda sonora em sua viagem pela cóclea, possibilitando uma estimulação simultânea das fibras nervosas ao longo da via auditiva proporcionando uma melhor sincronia neural e consequentemente o registro de respostas com maiores amplitudes. Este estudo visa analisar e comparar os resultados do Potencial Evocado Auditivo de Tronco Encefálico em neonatos nascidos a termo, utilizando os estímulos clique e iChirp, em diferentes intensidades de apresentação, analisando latência e amplitude da onda V, orelha testada e gênero. A casuística do estudo foi de 30 neonatos a termos, e o protocolo para registro do PEATE com estímulo clique e iChirp foi: polaridade rarefeita, 2048 varreduras, taxa de apresentação de 27,7 estímulos/s, filtro passa banda de 100 a 3000 Hz, ganho de 100k, janela de 12 ms para o clique e 24 ms para o iChirp. As intensidades pesquisadas com os dois estímulos foi de 60, 40 e 20 dB nHL. Na comparação dos resultados obtidos com os dois estímulos utilizados no estudo, em relação aos valores para a latência da onda V, observou-se que valores aumentados com o iChirp, nos três níveis de apresentação. Em relação a amplitude deste componente, observou-se que o estímulo iChirp foi capaz de gerar amplitudes maiores estatisticamente significantes quando comparado ao clique, também nas três intensidades pesquisadas. Houve discretas diferenças entre as orelhas e entre os gêneros para os valores de latência e amplitude da onda V com os diferentes estímulos utilizados, entretanto com pouca relevância clínica. Conclui-se que a utlização do estímulo iChirp pode ser interessante no campo do diagnóstico audiológico infantil, por evocar respostas com maiores amplitudes, nos três níveis de intensidade pesquisadas, desta maneira faciliando a identificação da onda V. Cabe ressaltar que quando utilizou-se o iChirp a latência da onda V apresentou-se maior quando comparada a pesquisa com o clique. As variáveis orelha testada e gênero apresentaram discretas diferenças que não foram consideras relavantes clinicamente.

Abstract Termination of pregnancy (TOP) is the most common gynaecological procedure, each year approximately 9500 TOPs have been performed in Finland in recent years. In recent decades the termination practice has changed. In Finland the traditional surgical method has been largely replaced by medical method. Commonly, women undergoing TOP are at their best reproductive age, and a high proportion of them will be pregnant again later in life. There has been a concern that TOP might lead to adverse outcomes in following pregnancies, or could affect future fertility. However, the long-term reproductive health effects of TOP, and especially the effects of medical TOP, are not well established. The aim of this study was to investigate the effects of medical TOP and the influence of inter-pregnancy intervals (IPIs) after TOP on the risk of adverse events in following pregnancies. The other part of the study assessed which factors are associated with future in vitro fertilization (IVF) treatment after TOP. In this large nationwide register-based study, the risks of preterm birth, low birth weight, SGA (small-for-gestational-age) infants and placental complications were similar among women giving birth following a single first-trimester medical TOP (n = 3441) compared with surgical TOP (n = 4853), and after a single second-trimester medical TOP (n = 416) compared with first-trimester medical TOP (n = 3427). Women who conceived < 6 months after TOP (n = 2956) had a slightly but significantly increased risk of preterm birth compared with women who conceived at 18 to < 24 months (n = 2076). A higher age and a lower number of previous terminations and deliveries at the time of TOP were associated with the IVF treatments in the future. TOP-associated factors, such as method or complications of TOP or gestational age at TOP did not have an association with IVF. This study provides further evidence on the safety of medical TOP as regards the following pregnancy. Well-timed subsequent pregnancy after TOP may help to avoid potential harmful consequences associated with preterm birth. The factors found to be associated with IVF treatments after TOP are those generally recognized risk factors for infertility. / Tiivistelmä Raskaudenkeskeytys on yleisin gynekologinen toimenpide; viime vuosina Suomessa on tehty keskimäärin 9500 keskeytystä vuosittain. Kahden viimeisen vuosikymmenen aikana raskaudenkeskeytysmenetelmien käytössä on tapahtunut merkittävä muutos. Lääkkeellinen menetelmä on lähes syrjäyttänyt perinteisen kirurgisen menetelmän Suomessa. Suurin osa keskeytykseen hakeutuvista naisista on nuoria ja huomattava osa suunnittelee raskautta myöhemmässä elämänvaiheessa. Tämä on herättänyt huolen siitä, onko raskaudenkeskeytyksellä vaikutusta seuraavan raskauden kulkuun tai myöhempään hedelmällisyyteen. Yhteneväistä laajaa näyttöä raskaudenkeskeytyksen, erityisesti lääkkeellisen menetelmän, pitkäaikaisvaikutuksista lisääntymisterveyteen ei kuitenkaan ole saatavilla. Tutkimuksen tarkoituksena oli selvittää lääkkeellisen raskaudenkeskeytyksen sekä keskeytyksen ja seuraavan raskauden välisen ajan vaikutuksia mahdollisiin haitallisiin tapahtumiin keskeytystä seuraavassa raskaudessa. Lisäksi selvitettiin, ovatko keskeytykseen liittyvät tekijät yhteydessä mahdolliseen myöhempään koeputkihedelmöityshoitoon (in vitro fertilization, IVF). Tässä laajassa valtakunnallisessa rekisteripohjaisessa tutkimuksessa ennenaikaisen synnytyksen, vastasyntyneen matalan syntymäpainon, pienikokoisena syntyneen lapsen ja istukkaongelmien riski oli samankaltainen yhden lääkkeellisen (n = 3441) ja kirurgisen (n = 4853) ensimmäisen raskauskolmanneksen keskeytyksen jälkeen. Myöskään ensimmäisen (n = 3427) ja toisen raskauskolmanneksen (n = 416) lääkkeellisen keskeytyksen välillä ei havaittu eroja kyseisissä haittatapahtumissa. Ennenaikaisen synnytyksen riski lisääntyi hieman naisilla, joilla keskeytyksen ja seuraavan raskauden välinen aika oli alle kuusi kuukautta (n = 2956) verrattuna naisiin, joilla raskauksien välinen aika oli 18–23 kuukautta (n = 2076). IVF-hoitoja lisäsivät naisen korkeampi ikä ja matalampi aikaisempien keskeytysten ja synnytysten määrä keskeytyshetkellä. Raskaudenkeskeytykseen liittyvät tekijät, kuten keskeytysmenetelmä, komplikaatiot tai raskausviikot keskeytyshetkellä, eivät sen sijaan liittyneet myöhempään hoitojen tarpeeseen. Tutkimus antaa lisätietoa lääkkeellisen raskaudenkeskeytyksen turvallisuudesta. Hyvin ajoitettu seuraava raskaus keskeytyksen jälkeen voi vähentää ennenaikaisen synnytyksen riskiä. IVF-hoidot keskeytyksen jälkeen liittyvät aiemmin tunnettuihin lapsettomuuden riskitekijöihin.

Magister Public Health - MPH / Kangaroo mother care (KMC) was first initiated in Colombia due to shortages of incubators and the incidence of severe hospital infections of new-born infants during hospital stay (Feldman, 2004). Currently it is identified by UNICEF as a universally available and biologically sound method of care for all new-borns, particularly for low birth weight infants (Department of Reproductive Health and Research, 2003) in both developed and developing countries. The Western Cape Provincial Government implemented a policy on KMC as part of their strategy to decrease the morbidity and mortality of premature infants in 2003 (Kangaroo Mother Care Provincial task team, 2003). Essential components of KMC are: skin-to-skin contact for 24 hours per day (or as great a part of the day as possible), exclusive breastfeeding and support to the motherinfant dyad. Successful implementation of KMC requires relevant education of nurses, education of mothers on KMC by nursing staff, monitoring of the implementation of KMC by nurses, planning for a staff mix with varying levels of skill and experience with KMC, the identification of institution specific barriers to the implementation of KMC, and the implementation of institution specific strategies to overcome these barriers (Wallin,et al., 2005; Bergman & Jurisco, 1994; Cattaneo, et al., 1998). This study aims to determine the knowledge of and attitude towards kangaroo mother care, of nursing staff and kangaroo mothers in the Eastern sub-district of Cape Town. / South Africa

La prématurité, définie par une naissance avant 37 semaines d’aménorrhées (SA), est une cause majeur de mortalité et de morbidité infantile. Comparés aux enfants nés à terme, les prématurés font face à des risques importants de troubles moteurs et cognitifs durant l'enfance, ainsi que de maladies chroniques et décès prématurés à l’âge adulte. La prématurité constitue un enjeu important de santé publique et en Europe, les taux varient entre 5 et 10%. Notre objectif pour cette thèse était de mieux comprendre les sources d’hétérogénéité des taux à l’échelle des pays. Dans un premier temps, nous avons effectué une revue exhaustive de la littérature qui montre que les caractéristiques maternelles, les pratiques médicales, et les méthodes d'estimation de l'âge gestationnel ont un impact sur les taux de prématurité. Cependant, ces facteurs n'expliquent pas l’ampleur des différences observées entre les pays. Puis, en utilisant des données sur les femmes enceintes, les nouveau-nés et les mort-nés dans 34 pays à revenus élevés de 1996 à 2010, nous avons établi que: 1) les différences d'enregistrement des naissances dans les pays à revenus élevés ont un impact limité sur les taux, sauf pour les naissances à 22-23 SA, 2) les tendances de PTB dans les pays sont associées à des variations plus importantes dans la distribution des âges gestationnels 3) et enfin, en utilisant les données d'un échantillon représentatif des naissances en France en 2010, qu’il existe des facteurs de risques maternels prénatals et socio-démographiques communs aux naissances avant terme (<37SA) et proche du terme à 37-38 SA. Viser à réduire les facteurs de risques de la naissance proche du terme et de la prématurité dans une approche conjointe pourrait apporter un nouvel élan à la prévention de la prématurité. Comparés aux enfants prématurés, les enfants nés proche du terme sont individuellement moins à risque, mais à l’échelle des pays ces enfants représentent environ une naissance sur quatre et ils contribuent de manière importante au fardeau de morbi-mortalité néonatale et infantile. Au niveau national, élargir les efforts de prévention de la prématurité à cette nouvelle population-cible pourrait avoir un plus grand impact sur la santé publique. / Preterm birth (PTB), defined as birth before 37 weeks, is a leading cause of infant mortality and morbidity. Compared to term infants, preterm infants face important risks of motor and cognitive impairments throughout childhood, as well as chronic diseases and premature death later in life. PTB represents a significant public health burden and in Europe, rates range between 5 and 10%. Such wide differences suggest that reductions may be possible, but there are few effective interventions, and these tend to target selected groups of high-risk pregnancies, based on clinical risk factors. Our aim for this thesis was to better appraise sources of population-level PTB rate variations and trends. First, we conducted an exhaustive review of the literature and found that maternal characteristics, reproductive policies, medical practices and methods of gestational age (GA) estimation affected PTB rates, but could not explain observed differences across countries. Next, using population-based data on pregnant women, newborns and stillbirths in 34 high-income countries from 1996 to 2010, we showed that: 1) reporting criteria for births and deaths affected PTB rates at early gestations and PTB rankings, but differences between countries with high and low rates are not just due to artefact 2) PTB trends were associated with broader shifts in countries’ gestational age GA distribution of births, and 3) using data from a representative sample of births in France in 2010, that there were shared maternal prenatal and socio-demographic risk factors for deliveries that did not reach full term, at 39 weeks GA. Our work confirms that recording differences in high-income countries have a limited impact on PTB rate variations. However, a broader focus on earlier delivery, including early term birth at 37-38 weeks, could shed light on the determinants of low PTB rates and provide a useful public health prevention paradigm.

Background: Adverse birth outcomes present a difficult and chronic challenge in Ontario, in Canada and in developed countries in general. Increasing proportions of preterm births, significant regional disparities and the high cost of treating all adverse birth outcomes have focused attention on explaining them and developing effective treatments. Methods: Birth outcomes and maternal characteristics for approximately 626,000 births, about 90% of births in 2005–2009, were linked to small geographic areas throughout Ontario. For each of four adverse outcomes: late preterm, moderate to very preterm, small for gestation age and still births, proportions of total births were calculated for the full province and for each small geographic area. Geographic hotspots of elevated rates were identified for each of the different adverse birth outcomes using the local Moran’s I statistic. Data for nine known ecologic and individual risk factors were then linked to the areas. Hierarchical regression analysis was used to model each of the outcomes for the full province and for dispersed local areas. The resulting models for the different outcomes were contrasted. Results: Significant geographic hotspots exist for each of the four outcomes. Hotspots for the different outcomes were found to be largely spatially exclusive. For like outcomes, predictive models differed markedly between local areas (i.e. local groups of hotspots) as well as between full-province and local areas. Ecologic level variables played a strong role in all models; the influence of individual level risk factors was consistently modified by ecologic risk factors except for small for gestational births. Conclusions: The finding of significant hotspots for different adverse birth outcomes indicates that certain geographic areas have aetiologies or patterns of predictors sufficient to create significantly elevated levels of particular outcomes. The finding that hotspots for the different adverse outcomes are largely exclusive implies that the aetiologies are specific; i.e., those that are sufficient to create significantly higher levels for one outcome do not also create significantly higher levels of others. The consistently strong role of ecologic level risk factors in modifying individual level risk factors implies that contextual characteristics are an important part of the aetiology of adverse birth outcomes. Differences in local area models suggest the existence of location-specific (rather than universal) aetiologies. The findings support the need for more careful attention to local context when explaining birth outcomes.

Cadre conceptuel et problématique : La cholestase hépatique est une pathologie à large éventail d’étiologies, affectant fréquemment les nouveau-nés. Un diagnostic approprié est essentiel pour la prise en charge clinique, le choix des traitements et l’amélioration du pronostic. Alors que les prématurés ont un risque accru de développement de la cholestase, les algorithmes de traitement ne proposent qu’une prise en charge unique, quel que soit l’âge gestationnel (AG) du patient. Objectif : Déterminer si le profil clinique, la prise en charge et le pronostic de la cholestase néonatale diffèrent selon l’AG. Méthodologie : Une étude de cohorte rétrospective de nouveau-nés atteints de cholestase et admis en néonatologie au CHU Sainte Justine entre janvier 2014 et décembre 2017 a été menée. La cholestase était définie par au moins deux valeurs consécutives de bilirubine conjuguée ≥ 34 μmol/L. La cohorte a été stratifiée en deux groupes d’AG : les extrêmes et les grands prématurés (< 32 semaines AG) et les prématurés modérés ou tardifs et naissances à terme (≥ 32 semaines AG). Résultats : 125 nouveau-nés sur 3 277 ont développé une cholestase. L’incidence globale était de 4% ; cette incidence était 5 fois plus élevée chez les nouveau-nés < 32 semaines d’AG comparativement aux ≥ 32 semaines d’AG. La cholestase était associée à une nutrition parentérale chez 91% des patients avec AG < 32 semaines et seulement 40% des patients avec AG ≥ 32 semaines (p < 0,01). Alors que l'acide ursodésoxycholique était plus prescrit aux nouveau-nés ≥ 32 semaines AG, les émulsions lipidiques à base d'huile de poisson étaient plus administrées aux nouveau-nés < 32 semaines AG, parmi les patients recevant une nutrition parentérale. Conclusion : La cholestase néonatale est associée à deux profils cliniques différents, basés sur l'AG. Nous recommandons que les tests diagnostics et la prise en charge clinique de la cholestase soient adaptés à l'AG. Une nouvelle approche pour l'évaluation d'un nourrisson atteint d'hyperbilirubinémie conjuguée est proposée. / Background and Aims: Cholestasis is a frequent neonatal disease that has a wide range of etiologies. Appropriate diagnosis is essential to clinical management, treatment choices and improvement of outcomes. Most references discuss neonatal cholestasis as one entity. The goal of this study was to determine if the clinical profile, management and outcome of cholestasis differ according to gestational age (GA). Methods: Medical records of infants with cholestasis in the division of neonatology at CHU Sainte Justine, between January 2014 and December 2017, were retrospectively reviewed. Cholestasis was defined as two or more consecutive conjugated bilirubin values ≥ 34μmol/L. The cohort was stratified into two groups: extremely to very preterm (< 32 weeks GA) and moderate to late preterm and term (≥ 32 weeks GA). Results: 125 of 3,277 patients developed cholestasis. Overall incidence of cholestasis was 4%. Incidence was 5 times higher in neonates < 32 weeks GA compared to neonates ≥ 32 weeks GA. Cholestasis was associated with parenteral nutrition in 91% of patients with GA < 32 weeks and 40% of patients with GA ≥ 32 weeks (p < 0.01). While ursodiol treatment was prescribed more to cholestatic neonates ≥ 32 weeks GA, fish oil lipid was administered more to neonates < 32 weeks GA, among patients receiving parenteral nutrition. Conclusions: Neonatal cholestasis was associated with two different clinical profiles based on GA. We recommend diagnostic tests and clinical management of neonatal cholestasis be adapted to GA. A GA-based approach to the evaluation of an infant with conjugated hyperbilirubinemia is proposed.

<p>Hormon rasta ima ključnu ulogu u mnogim fiziolo&scaron;kim procesima, anabolički efekti, stimulisanje rasta dugih kostiju, regulacija transkripcije gena u ciljnim ćelijama su uglavnom posredovani preko mitogenog polipeptida, insulinu sličan faktor rasta tip 1 (insulin like growth factor 1-IGF-1). Hormon rasta indukuje proizvodnju IGF-1 u jetri, koji reaguje sa receptorima ciljnih organa indukujući rast, odnosno IGF-1 posreduje svim stimulativnim dejstvima hormona rasta na kost, hrskavicu, rast mi&scaron;ić a i na metabolizam masti i ugljenih hidrata. U proceni redovnosti, bezbednosti i efikasnosti terapije hormonom rasta koristi se merenje koncentracije IGF-1 u serumu. Istraživanje je urađeno kao retrospektivno-prospektivna studija, a obuhvatilo je 80 pacijenata na terapiji hormonom rasta koja se kontroli&scaron;u i leče na Odeljenju za endokrinologiju, dijabetes i bolesti metabolizma Instituta za zdravstvenu za&scaron;titu dece i omladine Vojvodine u Novom Sadu. Istraživani uzorak je obuhvatio 80 pacijenata, od kojih 35 dece sa nedostatkom hormona rasta, 24 dece rođene male za gestacionu dob i 21 devojčicu sa Tarnerovim sindromom. Svi ispitanici su praćeni od početka primene hormona rasta i tokom prve dve godine terapije hormonom rasta. U ovom istraživanju su praćeni auksolo&scaron;ki i laboratorijski parametri u cilju ispitivanja odgovora na terapiju hormonom rasta. Praćene su bazalne vrednosti IGF-1 i promene nivoa IGF-1 u serumu tokom terapije hormonom rasta i kori&scaron;ćene da bi se ispitao odgovor na terapiju hormonom rasta, praćenjem brzine rasta, promena skora standardnih devijacija - SSD za telesnu visinu i ko&scaron;tanog sazrevanja. Ciljevi istraživanja su bili da se utvrdi povezanost vrednosti insulinu sličnog faktora rasta tip 1, brzine rasta i ko&scaron;tanog sazrevanja tokom terapije hormonom rasta. Takođe je poređena brzina rasta dece sa deficitom hormona rasta, devojčica sa T arnerovim sindromom i dece rođene male za gestaciono doba na terapiji hormonom rasta. U istraživanom uzorku, dvogodi&scaron;njim praćenjem terapije hormonom rasta je postignut dobar odgovor na terapiju, među decom sa nedostatkom hormona rasta je 71,5% postiglo normalnu telesnu visinu (&plusmn;2 SSDTV) posle dve godine terapije hormonom rasta, 79,2% dece rođene male za gestacionu dob i 42,9% devojčica sa Tarnerovim sindromom. Značajna zastupljenost dece prepubertetskog uzrasta na početku terapije hormonom rasta, među decom sa nedostatkom hormona rasta 77,2%, među decom rođenom malom za gestacionu dob 79,1% i među devojčicama sa Tarnerovim sindromom 90,5% &scaron;to je značajno uticalo na uspe&scaron;nost terapije. Tokom terapije hormonom rasta je utvrđeno povećanje brzine rasta i SSD TV kod sve tri grupe ispitanika. U sve tri grupe ispitanika je tokom terapije hormonom rasta utvrđen porast nivoa IGF-1 seruma i SSDIGF-1 i ubrzanje ko&scaron;tanog sazrevanja tokom terapije hormonom rasta. Za prvih &scaron;est meseci terapije nema statistički značajnih razlika među grupama u brzini rasta (p&gt;0,05), dok je za period prve i druge godine terapije hormonom rasta utvrđeno da postoji statistički značajna razlika među grupama (p&lt;0,05), da je brzina rasta kod devojčica za Tarnerovim sindromom statistički značajno manja i od brzine rasta kod dece sa nedostatkom hormona rasta (p &lt;0,05), i od brzine rasta kod dece rođene male za gestacionu dob (p&lt;0,05). Među decom sa nedostatkom hormona rasta i dece rođene male za gestacionu dob nema statistički značajne razlike u brzini rasta (p&gt;0,5). U ovom istraživanju je praćenjem auskolo&scaron;kih i laboratrijskih parametara tokom dvogodi&scaron;nje primene hormona rasta, konstruisano vi&scaron;e matematičkih modela za predviđanje odgovora na terapiju hormona rasta koji su statistički veoma značajani sa visokim koeficijentom vi&scaron;estruke linearne korelacije. U ovom istraživanju nije dobijena statistički značajna korelacija izmedju nivoa promene IGF-1 i brzine rasta za ceo uzorak, kao ni za decu sa nedostatkom hormona rasta, decu rođenu malu za gestacionu dob i devojčice za Tarnerovim sindromom. Nije dobijena statistički značajna korelacija izmedju nivoa promene IGF-1 i ubrzanja ko&scaron;tanog sazrevanja za ceo uzorak i za tri grupe pacijenata.</p> / <p>Growth hormone plays a key role in many physiological processes. The anabolic effects, the stimulation of growth of the long bones and the regulation of gene transcription in the target cells are mediated mainly via mitogenic polypeptide and insulin-like growth factor type 1 (insulin like growth factor 1-IGF-1). Growth hormone induces the production of IGF-1 in the liver, which interacts with receptors of the target organs inducing growth, that is, IGF-1 mediates all the stimulating effects of growth hormone on bone, cartilage, muscle growth and the metabolism of fats and carbohydrates. In assessing the regularity, safety and efficacy of growth hormone therapy, measuring the concentration of IGF-1 in serum is used. The survey was conducted as a retrospective-prospective study and involved 80 patients treated with growth hormone, monitored and treated at the Department of Endocrinology, Diabetes and Metabolic Diseases, at the Institute for Health Protection of Children and Youth of Vojvodina in Novi Sad. Investigated sample included 80 patients, of whom 35 children have growth hormone deficiency, 24 children were born small for gestational age and 21 girls with Turner syndrome. All the patients were monitored from the beginning of the administration of growth hormone and during the first two years of growth hormone therapy. In this study, auxological and laboratory parameters were monitored for the purpose of examining the response to treatment of growth hormone. The basal values of IGF-1 and changes in IGF-1 levels in serum, along with monitoring the rate of growth velocity and recent changes in standard deviation - SSD for body height and bone maturation, were monitored during growth hormone therapy and used for the evaluation of the response to growth hormone therapy. The objectives of the study were to determine the correlation of insulin-like growth factor type 1 values, the growth velocity and maturation of bone during growth hormone therapy. Also, the growth velocity in children with growth hormone deficiency was compared with the growth velocity in girls with Turner syndrome and in children born small for gestational age while treated with growth hormone. Two-year monitoring of growth hormone therapy in the study sample has show n good response to therapy. 71.5% of children with growth hormone deficiency, 79.2% of children born small for gestational age, and 42.9% of girls with Turner syndrome achieved normal body height (&plusmn; 2 SSDTV) after two years of growth hormone therapy. There was a significant share of children at prepubertal age at the beginning of growth hormone therapy: 77.2% of children with growth hormone deficiency, 79.1% of children born small for gestational age and 90.5% of girls with Turner syndrome, which significantly influenced the success of the therapy. During the growth hormone therapy there was an increase of growth velocity and SSD TV in all three groups of children. An increase in levels of IGF-1 serum and SSDIGF-1 and acceleration of bone maturation were determined in all three groups of patients during growth hormone therapy. For the first six months of therapy there was no statistically significant difference between groups in growth velocity (p&gt; 0.05), while the period of the first and second year of growth hormone therapy showed a statistically significant difference between groups (p &lt;0.05). The growth velocity in girls with Turner syndrome was significantly lower than the growth velocity in children with growth hormone deficiency (p &lt;0.05) and in children born small for gestational age (p &lt;0.05). Between children with growth hormone deficiency and children born small for gestational age there was no statistically significant difference in growth velocity (p&gt; 0.5). By monitoring auxological and laboratory parameters during the two years of application of growth hormone, several highly statistically significant mathematical models for predicting the response to treatment of growth hormone were constructed in this study with a high coefficient of multiple linear correlation. In this study, there was no statistically significant correlation between the level of change in IGF-1 and growth velocity for the entire sample, as well as for children with growth hormone deficiency, children born small for gestational age and girls for Turner syndrome. There was no statistically significant correlation between the level of change in IGF-1 and acceleration of bone maturation for the entire sample and for the three groups of patients.</p>

L’asthme est connu comme l’une des maladies chroniques les plus fréquentes chez la femme enceinte avec une prévalence de 4 à 8%. La prévalence élevée de l’asthme fait en sorte qu’on se préoccupe de l’impact de la grossesse sur l’asthme et de l’impact de l’asthme sur les issus de la grossesse. La littérature présente des résultats conflictuels concernant l’impact de l’asthme maternel sur les issus périnatales comme les naissances prématurées, les bébés de petit poids et les bébés de petit poids pour l’âge gestationnel (PPGA). De plus, les données scientifiques sont rares concernant l’impact de la sévérité et de la maîtrise de l’asthme durant la grossesse sur les issus périnatales. Donc, nous avons mené cinq études pour réaliser les objectifs suivants: 1. Le développement et la validation de deux indexes pour mesurer la sévérité et la maîtrise de l’asthme. 2. L’évaluation de l’impact du sexe du fœtus sur le risque d’exacerbation de l’asthme maternel et l’utilisation de médicaments antiasthmatiques durant la grossesse; 3. L’évaluation de l’impact de l’asthme maternel sur les issus périnatales; 4. L’évaluation de l’impact de la sévérité de l’asthme maternel durant la grossesse sur les issus périnatales; 5. L’évaluation de l’impact de la maîtrise de l’asthme maternel durant la grossesse sur les issus périnatales. Pour réaliser ces projets de recherche, nous avons travaillé avec une large cohorte de grossesse reconstruite à partir du croisement de trois banques de données administratives du Québec recouvrant la période entre 1990 et 2002. Pour les trois dernières études, nous avons utilisé un devis de cohorte à deux phases d’échantillonnage pour obtenir, à l’aide d’un questionnaire postal, des informations complémentaires qui ne se trouvaient pas dans les banques de données, comme la consommation de cigarettes et d’alcool pendant la grossesse. Nous n’avons trouvé aucune différence significative entre les mères de fétus féminins et de fétus masculins pour les exacerbations de l’asthme pendant la grossesse (aRR=1.02; IC 95%: 0.92 to 1.14). Par contre, nous avons trouvé que le risque de bébé PPGA (OR: 1.27, IC 95%: 1.14-1.41), de bébé de petit poids (OR: 1.41, IC 95%:1.22-1.63) et de naissance prématurée (OR: 1.64, IC 95%:1.46-1.83) était significativement plus élevés chez les femmes asthmatiques que chez les femmes non asthmatiques. De plus, nous avons démontré que le risque d’un bébé PPAG était significativement plus élevé chez les femmes avec un asthme sévère (OR:1.48, IC 95%: 1.15-1.91) et modéré (OR: 1.30, IC 95%:1.10-1.55) que chez les femmes qui avaient un asthme léger. Nous avons aussi observé que les femmes qui avaient un asthme bien maîtrisé durant la grossesse étaient significativement plus à risque d’avoir un bébé PPAG (OR:1.28, IC 95%: 1.15-1.43), un bébé de petit poids (OR: 1.42, IC 95%:1.22-1.66), et un bébé prématuré (OR: 1.63, IC 95%:1.46-1.83) que les femmes non asthmatiques. D’après nos résultats, toutes les femmes asthmatiques même celles qui ont un asthme bien maîtrisé doivent être suivies de près durant la grossesse car elles courent un risque plus élevé d’avoir des issus de grossesses défavorables pour leur nouveau-né. / Asthma is known as one of the most frequent chronic diseases encountered during pregnancy with prevalence estimated between 4 and 8%. The high prevalence of asthma during pregnancy results in some concerns about the impact of pregnancy on maternal asthma and also the impact of maternal asthma on perinatal outcomes. The literature presents conflicting results concerning the impact of maternal asthma during pregnancy on perinatal outcomes, such as preterm birth, low-birth-weight (LBW) infant and small-for-gestational-age (SGA) infant. Also, scientific evidence is scarce regarding the impact of asthma severity and control during pregnancy on these perinatal outcomes. We thus conducted a research project composed of five studies to achieve the following objectives: 1. to develop and validate two database indexes, one to measure the control of asthma and the other to measure asthma severity; 2. to evaluate the effect of fetal gender on maternal asthma exacerbations and the use of asthma medications during pregnancy; 3. to evaluate the impact of maternal asthma on adverse perinatal outcomes; 4. to evaluate the impact of the severity of asthma during pregnancy on adverse perinatal outcomes; 5. to evaluate the impact of adequately controlled maternal asthma during pregnancy on adverse perinatal outcomes. A large population-based cohort was reconstructed through the linking of three of Quebec’s (Canada) administrative databases covering the period between 1990 and 2002. A two-stage sampling cohort design was used to collect additional information on the women’s life-style habits by way of a mailed questionnaire for the three last studies. We have observed no significant differences between mothers of a female and male fetus as to the occurrence of asthma exacerbations (aRR=1.02; 95% CI: 0.92 to 1.14). We have found that the risk of SGA (OR: 1.27, 95% CI: 1.14-1.41), LBW (OR: 1.41, 95% CI:1.22-1.63) and preterm delivery (OR: 1.64, 95%CI:1.46-1.83) was significantly higher among asthmatic than non-asthmatic women. Moreover, our results showed that the risk of SGA was significantly higher among severe (OR:1.48, 95%CI: 1.15-1.91) and moderate asthmatic women (OR: 1.30, 95%CI:1.10-1.55) than mild asthmatic women. Also, mothers with adequately controlled asthma during pregnancy were found to be at higher risk of adverse perinatal outcomes than non-asthmatic women (SGA (OR:1.28, 95%CI: 1.15-1.43), LBW (OR: 1.42, 95%CI:1.22-1.66), and preterm deliveries (OR: 1.63, 95%CI:1.46-1.83)). According to our results, all asthmatic women even those with adequately controlled asthma should be closely monitored during pregnancy because they are at increased risk of adverse perinatal outcomes.

Os objetivos deste estudo foram correlacionar o tipo de lesão valvar mitral com eventos maternos e neonatais. É um estudo retrospectivo, observacional, realizado na Clínica Obstétrica do Hospital das Clínicas da Faculdade de Medicina de São Paulo. Foram coletados dados de 117 gestações em 111 mulheres com valvopatia mitral e 117 recém-nascidos resultantes destas gestações. No grupo estudado, foram observados 71 casos de gestantes portadoras de insuficiência mitral e 46 casos de gestantes portadoras de estenose mitral e seus 117 recém-natos. O tipo de lesão valvar, a estenose mitral, esteve significantemente relacionado piores classes funcionais (com predominância de CF III/IV), a maior necessidade de uso de medicamentos cardiovasculares, à maior freqüência de internação para compensação do quadro cardíaco, a maiores índices de parto cesárea, a menor média ponderal ao nascimento e a maior incidência de RNs pequenos para idade gestacional. Entretanto, a lesão valvar predominante não influiu com relevância estatística quanto à presença de complicações obstétricas, presença de co-morbidades clínicas, a complicações fetais, índice de Apgar < 7, e necessidade de UTI neonatal. A presença de valvopatia mitral na gravidez, principalmente a estenose mitral, acompanha-se de riscos maternos e perinatais / PURPOSE: To evaluate the maternal (clinical e obstetrical) and perinatal events related to the predominant valvar lesion in pregnant women with mitral valve disease. This is a Observational and retrospective study of 117 pregnancies in 111 patients with mitral disease, followed in a single tertiary center from January 2004 until August 2008. Clinical and obstetrical data were reviewed and analyzed according to the main type of valvar lesion (stenosis or insufficiency). The statistical analysis of the results was performed by chi-square test, Fishers exact test, and Mann-Whitney test. Among the 117 pregnancies (and neonates), there were 71 cases of predominant mitral regurgitation (MR group) and 46 with predominant mitral stenosis. The MS group presented more severe heart failure symptoms (functional class III and IV) during pregnancy, received more cardiovascular drugs and needed more hospital admissions due to cardiac reasons . Concerning perinatal events, MS presented higher rates of cesarean sections, smaller birthweight and higher incidence of SGA (small for gestational age, babies. Nevertheless, the predominant valvar lesion was not significantly related to other clinical co-morbidities, obstetrical or perinatal complications. Mitral valve disease in pregnancy is related to clinical and perinatal events, especially in patients with predominant mitral stenosis

Estudo longitudinal, prospectivo, comparativo de avaliação dopplervelocimétrica das artérias uterinas direita e esquerda em 37 gestantes normais em três períodos da gestação, acompanhadas na Clínica Obstétrica do HCFMUSP. Análise da relação S/D, índice de pulsatilidade e índice de resistência, relação com o número de incisuras e com posição da placenta. Foi observada redução nos valores dos índices durante a gestação. A relação S/D AUTE com placenta a direita apresentou média superior. A incidência de incisura foi maior no período entre a 16ª e a 24ª semana de gestação. A análise da relação entre os índices dopplervelocimétricos e a presença de incisura não teve resultados significativos / Prospective, longitudinal, comparative study of Doppler evaluation of the right and left uterine arteries of 37 healthy women with singleton pregnancies, performed in three periods of pregnancy, at the Pre-Natal Care Unit HCFMUSP. S/D ratio, pulsatility index and resistance index, number of notches and placental position were analysed. A decrease in the indices was observed with advancing gestation. When placenta was on the right side, the left uterine artery S/D ratio showed increased mean values. The incidence of uterine notch was higher between the 16th and 24th week of gestation in both arteries. No correlation was found between the presence of uterine notch and the placental position